File Download

There are no files associated with this item.

Supplementary

Conference Paper: Antibody therapy against granulin-epithelin precursor sensitizes liver cancer to chemotherapy

TitleAntibody therapy against granulin-epithelin precursor sensitizes liver cancer to chemotherapy
Authors
Issue Date2014
PublisherThe American Association for Cancer Research (AACR).
Citation
The 105th Annual Meeting of the American Association for Cancer Research (AACR), San Diego, USA, 5-9 April 2014, p. abstract no. 3764 How to Cite?
AbstractThe novel growth factor granulin-epithelin precursor (GEP, also named progranulin, acrogranin, or PC-derived growth factor) has shown to be upregulated in breast, ovary, prostate, liver and various human cancers. Our group has shown that GEP associated with chemo-resistance, recurrence and cancer stem cell properties in liver cancer [Gastroenterology 2011 and PLoS One 2011]. In the current study, we demonstrated that, both in vivo and in vitro, liver cancer cells that survived after chemotherapeutic agents demonstrated up-regulation of hepatic cancer stem cell marker CD133/GEP/ABCB5, and enhanced cancer stem cell properties, including colony formation and spheroid formation abilities. Importantly, combination of GEP antibody therapy and chemotherapy reversed the phenotypes induced by chemotherapy alone in the liver cancer cells and also the chemo-resistant subpopulations. Notably, combination of GEP antibody and cisplatin resulted in the eradication of all established intrahepatic human xenografts. This preclinical study demonstrated that combination treatment has the potential to be effective therapeutic regimen for GEP positive cancers.
DescriptionConference Theme: Harnessing Breakthroughs - Targeting Cures
Session: Resistance to Platins, Alkylating Agents, and Temozolamide: Experimental and Molecular Therapeutics 28
Poster Presentation 33
Persistent Identifierhttp://hdl.handle.net/10722/201360

 

DC FieldValueLanguage
dc.contributor.authorWong, CLen_US
dc.contributor.authorCheung, Pen_US
dc.contributor.authorYip, CW-
dc.contributor.authorChan, KF-
dc.contributor.authorNg, IOL-
dc.contributor.authorFan, ST-
dc.contributor.authorCheung, ST-
dc.date.accessioned2014-08-21T07:25:24Z-
dc.date.available2014-08-21T07:25:24Z-
dc.date.issued2014en_US
dc.identifier.citationThe 105th Annual Meeting of the American Association for Cancer Research (AACR), San Diego, USA, 5-9 April 2014, p. abstract no. 3764en_US
dc.identifier.urihttp://hdl.handle.net/10722/201360-
dc.descriptionConference Theme: Harnessing Breakthroughs - Targeting Cures-
dc.descriptionSession: Resistance to Platins, Alkylating Agents, and Temozolamide: Experimental and Molecular Therapeutics 28-
dc.descriptionPoster Presentation 33-
dc.description.abstractThe novel growth factor granulin-epithelin precursor (GEP, also named progranulin, acrogranin, or PC-derived growth factor) has shown to be upregulated in breast, ovary, prostate, liver and various human cancers. Our group has shown that GEP associated with chemo-resistance, recurrence and cancer stem cell properties in liver cancer [Gastroenterology 2011 and PLoS One 2011]. In the current study, we demonstrated that, both in vivo and in vitro, liver cancer cells that survived after chemotherapeutic agents demonstrated up-regulation of hepatic cancer stem cell marker CD133/GEP/ABCB5, and enhanced cancer stem cell properties, including colony formation and spheroid formation abilities. Importantly, combination of GEP antibody therapy and chemotherapy reversed the phenotypes induced by chemotherapy alone in the liver cancer cells and also the chemo-resistant subpopulations. Notably, combination of GEP antibody and cisplatin resulted in the eradication of all established intrahepatic human xenografts. This preclinical study demonstrated that combination treatment has the potential to be effective therapeutic regimen for GEP positive cancers.-
dc.languageengen_US
dc.publisherThe American Association for Cancer Research (AACR).-
dc.relation.ispartofAnnual Meeting of the American Association for Cancer Research (AACR)en_US
dc.titleAntibody therapy against granulin-epithelin precursor sensitizes liver cancer to chemotherapyen_US
dc.typeConference_Paperen_US
dc.identifier.emailWong, CL: h0894166@connect.hku.hken_US
dc.identifier.emailCheung, ST: stcheung@hkucc.hku.hken_US
dc.identifier.emailYip, CW: wallacey@hku.hk-
dc.identifier.emailNg, IOL: iolng@hkucc.hku.hk-
dc.identifier.emailFan, ST: stfan@hku.hk-
dc.identifier.emailCheung, ST: stcheung@hkucc.hku.hk-
dc.identifier.authorityCheung, ST=rp00457en_US
dc.identifier.hkuros233709en_US
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats